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Background: It has been proposed that asthma control may be achieved in part by
minimizing airway inﬂammation. The simultaneous effects of inhaled steroids associated
with long-acting b-agonists and leukotriene antagonists on pulmonary function and airway
inﬂammation are still largely unexplored in children with moderate persistent asthma.
Objectives: The aim of this study was to investigate the effects of add-on therapy with
long-acting b-agonists and leukotriene antagonists on FEV1 and exhaled nitric oxide levels
(FENO) in children.
Methods: Forty-eight steroid-naı¨ve atopic asthmatic children, 7–11 years of age, were
randomly treated in four groups for two consecutive one-month periods, as follows: (1)
ﬁrst month: budesonide 200 mg twice daily; second month: budesonide 400 mg twice daily;
(2) ﬁrst month: budesonide 200 mg twice daily+formoterol 9 mg twice daily; second month:
budesonide 200 mg twice daily+montelukast 5mg once daily; (3) ﬁrst month: budesonide
200 mg twice daily+montelukast 5mg once daily; second month budesonide 200 mg+formo-
terol 9 mg twice daily; (4) ﬁrst and second month: budesonide 400 mg twice daily.
Results: All treatments resulted in a signiﬁcant increase in lung function and a decrease in
FENO compared with values at baseline. Budesonide+montelukast in combination was the
most effective treatment for reducing FENO levels.
Conclusion: This study demonstrates that add-on therapy with montelukast plus low-dose
budesonide is more effective than the addition of long-acting b-agonists or doubling the
dose of budesonide for controlling FENO in asthmatic children.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
O, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FM, formoterol; FVC, forced vital
LABA, long-acting b2-agonists; LTRA, leukotriene antagonist; MK, montelukast.
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M. Miraglia del Giudice et al.1810Introduction The protocol had the ethical approval by the secondThe evidence that asthma is a chronic inﬂammatory disease
of the airways supports the regular use of an anti-
inﬂammatory treatment, even in patients with mild persis-
tent disease.1 Currently, inhaled corticosteroids (ICS)
represent the most effective anti-inﬂammatory treatment
for the majority of asthmatic patients with persistent
asthma.1 Nevertheless, potential side effects of long-term
treatment with high daily dosages have to be considered,
particularly in children. Based on this issue, the most recent
revisions of international guidelines for asthma management
suggest an add-on therapy with either long-acting b2-
agonists (LABAs) or leukotriene antagonists (LTRAs) as an
alternative to an increased dose of ICS in adults and children
with moderate persistent asthma.1 However, LABAs and
LTRAs are characterized by markedly different pharmacolo-
gic properties that could provoke substantially different
effects on the basic mechanisms of the disease,2,3 which are
largely unexplored in children.4
Exhaled nitric oxide (FENO) is considered a valid para-
meter for a non-invasive monitoring of airway inﬂamma-
tion5–8 and it has been shown to be a useful marker for
assessment of pharmacologic therapy for airway inﬂamma-
tion.9 Recently, it was shown that measurements of FENO
levels may be used to guide treatment of asthma.10 The aim
of this study was to investigate whether the different
treatment options proposed by international guidelines for
children with moderate asthma are comparable in control-
ling the disease, not only in terms of improving lung function
but also improving airway inﬂammation, as measured by
FENO levels.Methods
Subjects
Fifty-one steroid-naı¨ve atopic asthmatic children (27 girls
and 24 boys), from 7 to 11 years of age, attending the
Pediatric Department of Second University of Naples (Italy),
were screened in this study. All patients were sensitized to
house dust mites and met the criteria for the American
Thoracic Society deﬁnition of asthma.11 All children demon-
strated an increase of at least 12% in forced expiratory
volume in 1 s (FEV1) after administration of 200 mg of
salbutamol and were classiﬁed as moderate, persistent
asthmatics.1,11 A medical history was collected and children
underwent a physical examination, spirometry with rever-
sibility to b2-agonists, FENO measurement, and skin prick
test to the most common allergens. Three children were
unable to comply with one or more tests; therefore, 48
children were admitted to the study. The study was
performed out of season for seasonal allergens to avoid
the confounding effect of such exposure. Patients had not
received oral or ICS, LABAs, or LTRAs for at least 4 weeks
before admission to the study; the only treatment used
during that period was inhaled salbutamol. Children also did
not use b2-agonists within the 24-h period before lung
capacity measurements.University of Naples, and all subjects signed informed
consent.
Study design
This was a double-blind study in which 48 patients were
randomly allocated into one of four parallel groups of 12
patients each for two consecutive one-month periods, as
follows: (1) ﬁrst month: budesonide (BD) 200 mg twice daily;
second month: budesonide 400 mg twice daily (BD 400/BD
800 group); (2) ﬁrst month: budesonide 200 mg twice
daily+formoterol (FM) 9 mg twice daily; second month:
budesonide 200 mg twice daily+montelukast (MK) 5mg once
daily (BD 400+FM/BD 400+MK group); (3) ﬁrst month:
budesonide 200 mg twice daily+montelukast 5mg once daily;
second month budesonide 200 mg+formoterol 9mg twice
daily (BD 400+MK/BD 400+FM group); (4) ﬁrst and second
month: budesonide 400 mg twice daily (BD 800/BD 800
group). Since this was a spontaneous study with no support
of pharmaceutical industry and without ofﬁcial placebos or
study-dedicated preparations, in order to keep the patients
and the clinical investigators blind about the regimen of
treatment, the following procedures were undertaken.
Budesonide and formoterol Turbuhaler dedicated to the
study were prepared by a doctor not involved in the clinical
part of the study. The devices were unlabelled, those
dedicated to placebo formoterol were carefully emptied
and the reservoirs cleaned by suctioning with a vacuum
pump. A non-matching placebo for montelukast was
obtained by preparing a dedicated small sweet cherry-
tasting candy with a very similar shape, colour and taste of
the active drug. Furthermore, the patients had never
experienced before neither budesonide/formoterol nor
montelukast treatment and therefore were unable to
distinguish between active drug or placebo. An external
doctor (not participating to the evaluation of the patients)
prepared the study drugs and placebos, as well as the
randomization table. The parents received sealed packages
containing the study drugs, i.e. budesonide at one of the
above referred concentrations and either the combination
of active formoterol plus placebo montelukast or placebo
formoterol plus active montelukast. The sealed packages
were delivered when the patients had left the hospital and
they had returned the used drugs to the doctor who
prepared the packages, in order to keep the clinical
investigators blind about the treatment regimen for each
patient. A treatment randomization list was kept in a sealed
envelope in order to know the allocation of every patient in
the case of emergency.
Patients visited the clinic three times: immediately
before initiation of treatment, at the end of the Month 1,
and at the end of Month 2. At each visit, FENO and
spirometric measurements were performed.
Nitric oxide measurement
FENO was measured with a chemiluminescence analyzer
(Model 280 Nitric Oxide Analyzer, Severs Instrument Inc.,
Boulder, CO); the detection limit of the apparatus was 1–5
parts per billion (ppb), as required by ATS guidelines, with a
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Table 2 FENO Group A: 1st month budesonide (bud)
200mcg/bid and 2nd month bud 400mcg/bid; Group B:
1st month, bud 200mcg/bid+formoterol 9mcg/day; 2nd
month: bud 200mcg/bid+montelukast 5mcg/day; Group
C: 1st month: bud 200mcg/bid+montelukast 5mcg/day;
2nd month bud 200mcg/bid+formoterol 9mcg/day;
Group D: for two months were administered bud
400mcg/bid. T0: basal value T1: after the ﬁrst month
of treatment T2: after the second month of treatment.
T0 T1 T2
Group A 39.972.9 28.373.2 25.373.8
Group B 3873.7 24.873.2 18.173.7
Group C 38.774.3 1973.8 25.273.9
Group D 41.174.5 2774.5 27.774.7
Formoterol, montelukast, and budesonide in asthmatic children 1811resolution of 1 ppb. The analyzer was calibrated daily, using
a certiﬁed NO mixture. Exhaled NO was recorded with the
singlebreath method according to published guidelines.12
Children inhaled to total lung capacity from NO-free air and
exhaled a single breath (without nose clip) through a
mouthpiece at a mouth pressure of 45 cm water and at an
expiratory ﬂow of 50mL/s. Mouth pressure was displayed on
a computer screen as a prompt for the children to maintain a
steady ﬂow. The measurement was rejected if a stable ﬂow
was not maintained for at least 6 s of exhalation. Nitric
oxide was measured at the plateau and expressed in ppb.
Lung function and reversibility test
Following FENO measurements, lung function variables
forced vital capacity (FVC) and FEV1 were measured using
a dry spirometer (Vmax series 22; Sensormedics) according
to published guidelines.13 The best value of three measure-
ments was recorded and expressed as a percentage of the
predicted value. The reversibility test requires an increase
of more than 12% in FEV1 compared with baseline 15min
after inhalation of 200 mg salbutamol delivered by metered
dose inhaler.
Statistical analysis
Results for FENO and FEV1 are reported as means7standard
errors of the mean. Analysis of variance (ANOVA) was used to
compare FENO and spirometric values between and within
groups. Signiﬁcance was declared when Po0:05.
Results
There were no signiﬁcant differences in mean baseline FENO
and FEV1 among the four treatment groups (Tables 1 and 2).
BD 400/BD 800 group: After one month of treatment with
budesonide twice daily at 200 mg, mean FENO decreased from
39.970.8–28.370.9 ppb ðPo0:01Þ (Fig. 1B). At the end of
Month 2 (twice-daily treatment with 400 mg budesonide),
FENO was 25.571.1 ppb. The change is FENO from the end of
Month 1 to the end of Month 2 was not signiﬁcant. Mean FEV1
increased from 76.2%72.5% of predicted at baseline to
84.1%72.4% at the end of Month 1 and to 86.7%72.4% at theTable 1 FEV1 Group A: 1st month budesonide (bud)
200mcg/bid and 2nd month bud 400mcg/bid; Group B:
1st month, bud 200mcg/bid+formoterol 9mcg/day; 2nd
month: bud 200mcg/bid+montelukast 5mcg/day; Group
C: 1st month: bud 200mcg/bid+montelukast 5mcg/day;
2nd month bud 200mcg/bid+formoterol 9mcg/day;
Group D: for two months were administered bud
400mcg/bid. T0: basal value T1: after the ﬁrst month
of treatment T2: after the second month of treatment.
T0 T1 T2
Group A 76.278.7 8478.4 86.6711
Group B 75.377 94.2711.9 95.7712.8
Group C 7777.5 95.6710.5 97710.4
Group D 7975.9 8675.5 8975.6end of Month 2 (Fig. 1A). The increase from baseline to the
end of Month 2 was signiﬁcant ðPo0:05Þ.
BD 400+FM/BD 400+MK group: Mean FENO decreased from
38.071.1 ppb at baseline to 24.870.9 ppb at the end of
Month 1 ðPo0:01Þ for children treated with budesonide
200 mg+formoterol 9 mg twice daily (Fig. 1B). After switching
to budesonide 400 mg twice daily+montelukast 5mg once
daily, mean FENO further decreased to 18.271.1 ppb
ðPo0:01Þ at the end of Month 2. Mean FEV1 increased from
75.3%71.7% of predicted at baseline to 94.2%73.4% at the
end of Month 1 ðPo0:05Þ and further increased to
95.7%73.7% at the end of Month 2 (Fig. 1A). The increase
from baseline to the end of Month 2 was signiﬁcant
ðPo0:01Þ.
BD 400+MK/BD 400+FM group: FENO mean values de-
creased signiﬁcantly from 38.771.3 ppb at baseline to
19.071.1 ppb ðPo0:01Þ at the end of Month 1 (budesoni-
de+montelukast), whereas it increased to 25.271.1 ppb
ðPo0:05Þ at the end of Month 2 after 1 month of treatment
with budesonide+formoterol (Fig. 1B). Mean FEV1 increased
from 77.0%72.2% of predicted to 95.7%73.0% at the end of
Month 1 ðPo0:05Þ and to 97.0%71.6% at the end of Month 2
(Fig. 1A). The increase from baseline to the end of Month 2
was signiﬁcant ðPo0:01Þ.
BD 800/BD 800 group: After one month of therapy with
budesonide 400 mg twice daily, mean FENO decreased from
41.171.3 ppb to 27.171.3 ppb ðPo0:01Þ (Fig. 1B). Little
change was noted after the second month of treatment with
budesonide 400 mg (27.771.4 ppb). The change from base-
line to the end of Month 2 was signiﬁcant ðPo0:01Þ. At the
end of one month, mean FEV1 increased from 79.0%71.6% of
predicted to 86.0%71.6% (Fig. 1A). At the end of Month 2,
mean FEV1 had increased to 89.071.6%. The increase from
baseline to the end of Month 2 was signiﬁcant ðPo0:05Þ.
Between-group comparisons: Mean FENO was signiﬁcantly
lower after one month of treatment for children who had
received budesonide+montelukast (BD 400+MK/BD 400+FM
group) versus all other groups ðPo0:001Þ. Mean FEV1 for this
treatment regimen also was signiﬁcantly higher at the end
of one month of treatment compared with the value for the
BD 400/BD 800 group treated twice daily with budesonide
200 mg.
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Figure 1 Changes in FEV1 (panel A) and in FENO (panel B) for the four groups of children (mean+standard error). Group A: 1st month
budesonide (bud) 200mcg/bid and 2nd month bud 400mcg/bid; Group B: 1st month, bud 200mcg/bid+formoterol 9mcg/day; 2nd
month: bud 200mcg/bid+montelukast 5mcg/day; Group C: 1st month: bud 200mcg/bid+montelukast 5mcg/day; 2nd month bud
200mcg/bid+formoterol 9mcg/day; Group D: for two months were administered bud 400mcg/bid. T0: basal value T1: after the ﬁrst
month of treatment T2: after the second month of treatment. For statistical signiﬁcance please refer to the result section of the
text.
M. Miraglia del Giudice et al.1812At the end of Month 2, the BD 400+FM/BD 400+MK group
treated with budesonide+montelukast had a signiﬁcantly
greater decrease in FENO than did the other groups
ðPo0:001Þ. No signiﬁcant difference was observed for FEV1
among treatment groups at this evaluation time.Discussion
The present study demonstrated how the addition of
montelukast to low dose (200mcg bid) budesonide is able
to induce an adjunctive effect on FENO reduction as
compared to both higher dosage (400mcg bid) of budesonide
and add-on therapy of formoterol to low dose budesonide.
Previous studies comparing the effect of LABAs with LTRAs
in asthmatic patients not controlled by ICS alone determined
a better effect with the addiction of LABA.14–16 Never-
theless, a recent study in a large population of patients
uncontrolled by ICS alone reported a better response to
rescue medication and control of exercise-induced symp-
toms with montelukast than with salmeterol.17 A recent
meta-analysis of results up to the beginning of 2004
concluded that, in asthmatic adults for whom an add-on
treatment to low-dose ICS was required, LABAs were
superior to LTRAs in preventing asthma exacerbations,
improving lung function, symptoms, and reducing in the
use of rescue medications.18 Most of the available compara-
tive studies, including those considered in the meta-
analysis,18 are based on lung function or symptom reports.
However, previous reports have demonstrated that these
LABAs and LTRAs are characterized by substantially different
effects on FENO.
2,3 In fact, whereas LABAs have been shown
to have no effect on FENO in children with mild asthma,
19
montelukast was able to reduce FENO when it was used
either as a monotherapy20 or added to ICS.21 More recently,
Buchvald et al.22 have compared the effects of salmeterol
versus montelukast add-on therapy on FENO in asthmatic
children undergoing regular maintenance treatment with a
daily dose of 400mcg of budesonide. Studies show that
levels of FENO were higher after the addition of salmeterol,
as compared with either placebo or montelukast.22Several reports have emphasized the importance of
assessing airway inﬂammation in designing appropriate
therapeutic strategies for asthma control. Green et al.23
showed that a greater reduction in asthma exacerbation was
achieved by minimizing eosinophilic airway inﬂammation
rather than by following standard care. Measurement of
FENO levels has been proposed as a practical guide to
treating asthma.24 In the present study, if we consider the
changes in FENO with those observed for FEV1 in the two
groups with add-on therapy we might speculate that these
parameters are differently inﬂuenced by the therapeutic
strategies. In fact, FENO and FEV1, improved signiﬁcantly for
two groups treated with add-on therapy (groups B and C) in
the ﬁrst period of treatment. In the second phase of the
study, instead only the changes in FENO, but not in FEV1
reﬂect the switching effect from the therapeutic options.
The FEV1 changes observed after the ﬁrst month only in the
groups treated with either formoterol or montelukast
conﬁrm that in montelukast has a positive effect on lung
function in children as recently demonstrated by two studies
by Straub.22,23 The data from the present study regarding
FEV1 variations during treatment are partially in contrast
with those presented by Buchvald et al.22 In fact, in that
study, the group treated with LABA was the only one with
signiﬁcant increase in FEV1, whereas the present data
suggest that both formoterol and montelukast were able
to induce an increase in FEV1 at T1. However, when
comparing the two studies in terms of lung function, the
main difference is represented by the baseline level of FEV1,
being 101% of predicted in children participating to
Buchvald’s study22 (treated with 400mcg/d maintenance
dose of inhaled budesonide at the time of admission) in
contrast to levels below 80% of predicted value in children
participating to the present study (who did not receive
inhaled steroids until one month before enrolment). The
higher baseline levels in FEV1, with little room for improve-
ment, may, therefore, contribute to explain the lack of
effect on lung function for the group treated with
montelukast in the study by Buchwald.22 Similarly, the
different therapeutic regimens may in part explain the
different changes in FENO levels observed in the two studies.
In fact, in the present study, the FENO levels at baseline were
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Formoterol, montelukast, and budesonide in asthmatic children 1813not inﬂuenced by previous treatment with ICS and, there-
fore, it was possible to show more evident changes during
the study periods, with no ﬂoor effect.
Since FENO, but not FEV1, can reﬂect airway inﬂamma-
tion, an overall evaluation of the changes in the investigated
parameters during this study allow to speculate that add-on
therapy with montelukast, but not formoterol, is able to
exert an adjunctive anti-inﬂammatory effect to low and
medium dose budesonide in asthmatic children. In addition,
the results of this study show that no difference in the
investigated parameters could be observed between the two
dosages of budesonide, therefore inducing to support the
choice of an add-on therapy rather than an increase in the
daily regimen of inhaled steroid in children not well
controlled with low doses of budesonide.
In conclusion, this study has demonstrated that add-on
therapy with montelukast to low dosage of budesonide is
more effective than the addition of LABA or doubling the
dose of budesonide in controlling airway inﬂammation
measured as FENO in asthmatic children.
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